Goldfinch Bio today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal – Novel Mechanisms in Renal Disorders , at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal – Novel Mechanisms in Renal Disorders, at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022 at 3:30 p.m. ET.
About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis by applying precision medicine to pioneer the discovery, development and commercialization of kidney disease treatments. Our lead program, GFB-887, is a precision-based podocyte-targeting small molecule inhibitor of TRPC5, which has demonstrated clinical proof-of-concept as a novel treatment of focal segmental glomerulosclerosis. Visit us at www.goldfinchbio.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005340/en/
Contacts
Goldfinch Bio:
Investors:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media:
Liz Melone
lmelone@goldfinchbio.com
Source: Goldfinch Bio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220802005340/en
